Literature DB >> 30676411

Anterior Chamber XEN Gel Stent Movements: The Impact on Corneal Endothelial Cell Density.

Kevin Gillmann1, Giorgio E Bravetti1, André Mermoud1, Kaweh Mansouri1,2.   

Abstract

INTRODUCTION: Although there are several examples of glaucoma drainage devices' dislocations in the literature, the movement of XEN gel stents is scarcely documented, and the impact of such displacements on the corneal endothelium remains unknown. In light of the recent global market withdrawal of the CyPass microstent over concerns with regard to endothelial cell loss, we present a case of XEN gel stent dislocation into the anterior chamber, with localized corneal damage. CASE REPORT: We describe the case of a 64-year-old female patient who underwent bilateral XEN gel stent implantation for normal-tension glaucoma. While right eye surgery was uneventful, intraocular pressure increased in the left eye, and examination revealed a flat filtration bleb with no microstent visible through the conjunctiva. A 3 mm segment of the XEN stent was visible within the anterior chamber, with corneal contact during eye movement and blinking. Endothelial cell density was measured twice 1 month apart before the XEN gel stent was replaced. DISCUSSION: First, our observations confirm that XEN gel stents can dislocate and advance within the anterior chamber. We speculate that this displacement was caused by regular eye rubbing after surgery. Second, this report illustrates that the position of a drainage device within the anterior chamber is dynamic and significantly influenced by eye movements and blinking. Finally, occasional corneal contact of a XEN gel stent can cause a reduction in endothelial cell density of 2.1% in a month, which represents 46.2% of the annual endothelial loss observed by Tan and colleagues in patients with a Baerveldt tube (4.54% annual decrease).

Entities:  

Year:  2019        PMID: 30676411     DOI: 10.1097/IJG.0000000000001200

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  10 in total

1.  Effective treatment of a normal-tension glaucoma patient with bilateral ab externo XEN Gel Stent implantation.

Authors:  James M Harris; David Solá-Del Valle
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-28

Review 2.  Evaluating glaucoma surgeries in the MIGS context.

Authors:  Deepika Dhingra; Shibal Bhartiya
Journal:  Rom J Ophthalmol       Date:  2020 Apr-Jun

3.  Migration of XEN45 Implant: Findings, Mechanism, and Management.

Authors:  Zaria C Ali; Dawnn I Khoo; Francessco Stringa; Vikas Shankar
Journal:  J Curr Glaucoma Pract       Date:  2019 May-Aug

4.  One-Year Comparative Evaluation of iStent or iStent inject Implantation Combined with Cataract Surgery in a Single Center.

Authors:  Ricardo Augusto Paletta Guedes; Daniela Marcelo Gravina; Jonathan Clive Lake; Vanessa Maria Paletta Guedes; Alfredo Chaoubah
Journal:  Adv Ther       Date:  2019-08-22       Impact factor: 3.845

5.  Second-generation trabecular micro-bypass stent implantation: Retrospective analysis after 12- and 24-month follow-up.

Authors:  Raphael Neuhann; Tobias Neuhann
Journal:  Eye Vis (Lond)       Date:  2020-01-10

6.  Real-world Case Series of iStent or iStent inject Trabecular Micro-Bypass Stents Combined with Cataract Surgery.

Authors:  David Manning
Journal:  Ophthalmol Ther       Date:  2019-08-17

7.  Corneal Endothelial Cell Changes After Phacoemulsification Combined with Excisional Goniotomy with the Kahook Dual Blade or iStent: A Prospective Fellow-Eye Comparison.

Authors:  Syril Dorairaj; Goundappa K Balasubramani
Journal:  Clin Ophthalmol       Date:  2020-11-24

8.  Endothelial cell loss 5 years after Preserflo MicroShunt implantation: About two cases.

Authors:  Chloé Chamard; Sirine Hammoud; Elisa Bluwol; Yves Lachkar
Journal:  Am J Ophthalmol Case Rep       Date:  2021-12-08

9.  Outcomes of Deep Sclerectomy following Failed XEN Gel Stent Implantation in Open-Angle Glaucoma: A Prospective Study.

Authors:  Giorgio Enrico Bravetti; Kevin Gillmann; Harsha L Rao; André Mermoud; Kaweh Mansouri
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

10.  PreserFlo MicroShunt® exposure: a case series.

Authors:  Roxane Bunod; Mathieu Robin; Juliette Buffault; Chafik Keilani; Antoine Labbé; Christophe Baudouin
Journal:  BMC Ophthalmol       Date:  2021-07-10       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.